Brief: PaxMedica Achieves Key Milestone In The Development Of PAX-101 And Provides Update On Potential NDA Submission
11/04/2024 22:36
April 11 (Reuters) - PaxMedica Inc PXMD.O :
* PAXMEDICA ACHIEVES KEY MILESTONE IN THE DEVELOPMENT OF
PAX-101
AND PROVIDES UPDATE ON POTENTIAL NDA SUBMISSION
* PAXMEDICA INC - ANNOUNCED COMPLETED EXECUTION OF ITS THREE
PIVOTAL REGISTRATION/VALIDATION BATCHES OF PAX-101
Source text for Eikon: ID:nGNX5W9xDS
Further company coverage: PXMD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kuvatris Therapeutics
See all newsBrief: PaxMedica Responds To Emergency Request For IV Suramin And Commits To Provide Immediate Access To PAX-101
PaxMedica rises on Malawi's request for access to sleeping sickness drug
Brief: Paxmedica Receives Emergency Request For Iv Suramin From African Health Ministry For Use In Treating Fatal Sleeping Sickness
Brief: PaxMedica Achieves Key Milestone In The Development Of PAX-101 And Provides Update On Potential NDA Submission
Brief: Paxmedica Announces Pricing Of $7.0 Million Public Offering